Foundation Medicine

The company was founded by Alexis Borisy in 2010. Foundation Medicine was acquired by Roche for $2.4 billion in 2018. The company develops a number of genomic panel tests that can be used for at least five tumor types – ovarian, lung, breast, colorectal, and melanoma – and can also be used in conjun...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Psychedelic therapeutics company Cybin applies for patent for digital therapeutics platform

News Commentary | July 21, 2021

Cybin, a biotech company that focuses on psychedelic drug therapies for psychiatric disorders, is looking to patent a digital therapeutic platform to support its product offerings. It is not the first psychedelic company to do so; however, Cybin is unique in that it is looking to holistically ... Not part of subscription

Regulus Therapeutics

Company Profile | December 01, 2021

Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription

Pfizer partnering with Alex Therapeutics to develop nicotine-addiction DTx

News Commentary | February 08, 2022

Pfizer has partnered with Stockholm‑based DTx (digital therapeutics) maker Alex Therapeutics to deploy artificial intelligence (AI)‑based digital therapeutics. The Alex DTx platform combines cognitive‑based therapy and acceptance and commitment therapy with AI to offer personalized treatment plans. ... Not part of subscription